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ABSTRACT
Background and objectives: Vital signs are usually
recorded at 4–8 h intervals in hospital patients, and
deterioration between measurements can have serious
consequences. The primary study objective was to
assess agreement between a new ultra-low power,
wireless and wearable surveillance system for
continuous ambulatory monitoring of vital signs and a
widely used clinical vital signs monitor. The secondary
objective was to examine the system’s ability to
automatically identify and reject invalid physiological
data.
Setting: Single hospital centre.
Participants: Heart and respiratory rate were recorded
over 2 h in 20 patients undergoing elective surgery and
a second group of 41 patients with comorbid
conditions, in the general ward.
Outcome measures: Primary outcome measures
were limits of agreement and bias. The secondary
outcome measure was proportion of data rejected.
Results: The digital patch provided reliable heart rate
values in the majority of patients (about 80%) with
normal sinus rhythm, and in the presence of abnormal
ECG recordings (excluding aperiodic arrhythmias such
as atrial fibrillation). The mean difference between
systems was less than ±1 bpm in all patient groups
studied. Although respiratory data were more frequently
rejected as invalid because of the high sensitivity of
impedance pneumography to motion artefacts, valid
rates were reported for 50% of recordings with a mean
difference of less than ±1 brpm compared with the
bedside monitor. Correlation between systems was
statistically significant (p<0.0001) for heart and
respiratory rate, apart from respiratory rate in patients
with atrial fibrillation (p=0.02).
Conclusions: Overall agreement between digital
patch and clinical monitor was satisfactory, as was the
efficacy of the system for automatic rejection of
invalid data. Wireless monitoring technologies, such as
the one tested, may offer clinical value when
implemented as part of wider hospital systems that
integrate and support existing clinical protocols and
workflows.
INTRODUCTION
Patients continue to suffer unanticipated
adverse events despite innovations such as
early warning and scoring systems. In most
hospital patients, ‘vital signs’ measurements
are taken manually and recorded only inter-
mittently, commonly at 8 h intervals, unless
they have previously been identiﬁed as at
particular risk of deterioration.
Therefore, deterioration can have serious
consequences before it is recognised. Recent
reports1 2 have highlighted that many
patients still fall through this ‘safety net’,
resulting in signiﬁcant illness and even
Strengths and limitations of this study
▪ The study presented here was conducted
between 22 October 2009 and 15 July 2010, and
consisted of an early evaluation of the agreement
between a miniature, wireless, ‘digital patch’
system and a widely used clinical monitor for the
reporting of respiration and heart rate.
▪ The patient population comprised one group of
patients who were undergoing elective surgery
and one group of patients with a variety of rele-
vant comorbid conditions.
▪ Agreement between the two methods was gener-
ally good for the majority of situations tested.
The current form of the patch was not found to
be suitable for use in patients with aperiodic
arrhythmias such as atrial fibrillation.
▪ Clinical and statistical review of the data con-
firmed that the digital patch algorithm was reject-
ing invalid heart rate and respiratory rate data
appropriately. The device would need to be used
as part of a wider system and nursing workflow.
▪ The techniques for monitoring respiratory rate
used different physical principles; neither would
be regarded as a ‘gold’ standard. However, both
techniques are in wide current use and so the
comparison is clinically relevant.
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death, which might have been averted had the deterior-
ation been identiﬁed earlier. This has led to a focus on
early warning scoring systems designed to identify such
deteriorations and deliver faster care to the patient.
However, such systems are limited by the frequency with
which vital signs can practicably be measured.
A landmark study from East London3 identiﬁed
physiological evidence of impending deterioration some
hours before collapse in a substantial proportion of
patients admitted to intensive care during an emergency.
Respiratory rate (RR) was shown to be particularly sensi-
tive, but was often not accurately recorded or acted on.
A further study from Portsmouth, UK, determined that
initial response to deterioration was often capable of
improvement.4
The issue of organising and delivering emergency
responses, and their impact on improving patient out-
comes remains somewhat controversial.5 However, the
beneﬁts of early identiﬁcation of deterioration in patient
status due, for example, to onset of infection or post-
operative haemorrhage, are unarguable; the question is
how to achieve this.
A recent development is the adoption of the National
Early Warning Score (NEWS).6 This consists of a series
of vital signs with graded scoring which sum up to form
the NEWS; there is clearly an opportunity for technol-
ogy to populate this score and provide alerting systems.
It is not practicable to attach all patients to monitors
and indeed, the consequent reduction of mobility would
itself increase the likelihood of adverse events such as
blood clots and chest infections; such a solution would
also be very expensive. Thus, the risk–beneﬁt ratio
would seem to favour ‘static’ monitoring for very ill
patients in intensive and high-dependency units, but the
issues are more ﬁnely poised for less-dependent patients
in other parts of the hospital.
New wireless technology may allow increased surveil-
lance of patients’ status without the inconvenience of phys-
ical attachment to immobile monitoring systems, allowing
patients to move freely around their bed spaces, rooms
and ﬂoor areas. Recent advances in miniaturisation of
electronic circuits and computer technology, together
with progress in battery and radio systems, has raised the
possibility that an unobtrusive, low-cost surveillance system
can be attached to large numbers of hospital patients.
These systems can potentially capture and record data on
heart rate (HR), RR and temperature (and other poten-
tially signiﬁcant biological signals). They can then transmit
these data wirelessly via low-power radio to receivers in the
vicinity (within 10 m) for onward transmission to central
stations, to accelerate clinical response.
The objective of this study was to evaluate the perform-
ance of a wireless, digital patch system (SensiumVitals,
Sensium Healthcare Ltd, London, UK) in the hospital
environment, by gathering data from patients and compar-
ing these with data synchronously obtained from patients
monitored with a widely used conventional bedside clin-
ical monitor. The precise goals were twofold: ﬁrst, to assess
the performance of the SensiumVitals digital patch in a
clinical environment and second, to evaluate the ability of
the wireless monitoring system to reject corrupted data
and thus avoid/minimise the incidence of false alarms or
the erroneous reporting of inappropriately reassuring
data. Thus, the primary research aim was to measure
agreement with outcome measures of limits of agreement
and bias. The secondary aim was to evaluate rejection fre-
quency and appropriateness.
METHODS
Study procedure and participants
The study was performed in clinical areas at St Mary’s
Hospital, London, part of Imperial College Healthcare
National Health Service Trust. All patients gave written
informed consent.
This single-centre evaluation study compared the
ability of the wireless technology to acquire, transmit
and log physiological variables in a clinical context. The
reference clinical device was a conventional bedside clin-
ical monitor (IntelliVue MP30, Philips, Amsterdam, The
Netherlands) currently in clinical use within St Mary’s
Hospital.
Patients aged 18–85 years were eligible for enrolment.
Two groups were studied: group 1 consisted of 20
American Society of Anesthesiology (ASA) 1–2 patients
who were undergoing elective surgery; group 2 com-
prised 41 patients who had comorbid states which were
felt to present particular challenges to the technology:
low voltage or abnormal ECG morphologies, atrial ﬁbril-
lation, morbid obesity (deﬁned as a body mass index
(BMI) >30 kg/m2), and diabetes mellitus. Patients with
pacemakers, implantable deﬁbrillators or neurostimula-
tors were excluded; patients who were eligible for group
2 were excluded from group 1.
To minimise disruption to standard workﬂow and
practice, group 1 patients were studied in the operating
room while awaiting or recovering from routine surgery;
group 2 patients were studied while resting in bed in the
ward or clinical areas of St Mary’s Hospital.
Following informed consent, a digital patch (see below)
was attached as per manufacturer’s instructions to the
patient’s chest using two standard disposable ECG electro-
des (Red-Dot2560 3M, St Paul Minn). The patient was
then connected to the IntelliVue MP30 monitor via stand-
ard (three lead) ECG leads. The impedance pneumogra-
phy (IP) option was then disabled and RR measured
through the MP30 using capnography with standard
sidestream analysis via nasal canullae (Microstream,
OridionCapnography Inc, Needham, Massachusetts,
USA). This was necessary because IP is an active measure-
ment technique that relies on the injection of a small AC
current via the ECG electrodes. Simultaneous use of two
IP systems would cause direct interference between the
two, resulting in corrupted data.
It should be noted that the two methods for measure-
ment of RR are fundamentally different and exhibit
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different and uncorrelated experimental errors. For
example, capnography may give a more accurate
reading than IP during periods of gross patient move-
ment, but the IP technique may provide a truer reading
than capnography during periods when the patient
breathes through the mouth. Thus, the major aim of the
study was not to assess the accuracy of IP, which is typic-
ally validated using patient simulators or patients lying
still, but to evaluate how well the two different methods
compare and to assess the ability of the processing algo-
rithms to reject invalid data and minimise false alarms
under realistic hospital conditions.
Once the digital patch had been activated and was
transmitting, it was registered with the wireless recorder
and time-stamped data recorded on a laptop computer.
Data were acquired simultaneously from the Intellivue
monitor via Trendface software (Ixellence GmbH,
Wildau, Germany) with the patient at rest and recorded
on the same computer. Data were collected for up to 2 h
provided that it was clinically convenient. The digital
patch was removed for a time if the patient required
surgery involving diathermy.
How the digital patch works
The SensiumVitals digital patch is a lightweight,
energy-efﬁcient, single-use device that uses the Sensium
chip to monitor patients’ HR, RR and temperature in a
hospital environment. It was designed as an ambulatory
wireless monitoring alternative for patients throughout
their stay in the general hospital ward, with no need to
recharge the batteries. Several patents have been
granted for the SensiumVitals technology (patent publi-
cation numbers available on request).
This single-lead device can be easily attached to the
patient’s chest by means of two self-adhesive conven-
tional ECG electrodes (separated by approximately
10 cm), as shown in ﬁgure 1. Each patch wirelessly links
and transmits the vital signs to dedicated intranet hot
spots (bridges) potentially installed throughout the hos-
pital, which ultimately convey the information to a
central monitoring station/server (ﬁgure 1). Patients
can be tracked and monitored unobtrusively when
wearing the patch. The Sensium chip is a custom design
which integrates the sensor processing and wireless com-
munication functions into a single piece of low-cost
silicon, which translates into a lightweight patch and low
manufacturing cost. Therefore, the sales price is eco-
nomic for ‘one per patient per stay’ use, with the patch
being discarded when the patient is discharged, remov-
ing the need for cleaning and sterilisation to prevent
cross-contamination.
When the patch is activated, it records respiratory (by
IP) and ECG activity in a sequential and cyclical fashion.
Every 2 min, the patch records a 30 s segment of ECG, fol-
lowed by a 60 s segment of respiratory signal; thus the indi-
vidual vital signs measurements are sequential,
independent and non-continuous. Once a physiological
signal is fully acquired, it is processed by its associated
embedded algorithm inside the inbuilt processing unit,
which results in transmission of the average values (ie, HR
as beats per minute (bpm) or RR as breaths per minute
(brpm)) to the nearest hot spot for onward transmission
to the central monitoring system. Consequently, the algo-
rithms on the chip are energy efﬁcient and afford compar-
able accuracy to that of other types of monitoring devices.
In addition, the algorithms were also designed to identify
and reject physiological signals corrupted by signiﬁcant
sources of noise inherent to the ambulatory nature of wire-
less monitoring. This means that the system is embedded
with a noise-detection strategy capable of automatically
detecting and discarding erroneous calculations that arise
from raw respiratory and ECG signals severely corrupted
by electrical or motion artefacts.
At the end of each measurement period (typically
2 min cycle time), the calculated HR and RR values are
transmitted from the patch to a ‘hot spot’ and then on
Figure 1 The end-to-end monitoring system for wireless continuous monitoring of vital signs.
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to a storage database, providing updates to caregivers on
patients’ current vital signs and notifying them if these
deviate outside predeﬁned limits. A key goal during the
development of the patch was to minimise the occur-
rence of false alarms—that is, when a caregiver receives
a notiﬁcation, but the patient’s vital signs remain within
the speciﬁed limits. Since false alarms cause disruption
to the caregiver’s routine as they attend to the patient, a
system with a high incidence of false alarms may actually
hinder the caregiver’s work rather than provide informa-
tion that helps to deliver improved quality of care. False
alarms due to motion artefact are minimised through
the rejection of corrupted ECG and/or respiratory
signals as described below.
The Sensium chip contains two algorithms for deter-
mination of HR and RR, respectively. HR is obtained
using a predictive strategy that calculates this variable
based on the duration of R-R intervals. This approach,
based on previous developments in QRS detection,7 8
consists of two stages. First, digital signal processing tech-
niques are applied to minimise unwanted artefacts in
the signal (such as those produced by external sources
as static currents, muscular electrical activity and elec-
trode–electrolyte charge disturbances resulting from
patients’ motion), and to increase the energy of the fre-
quency components of the ECG signal linked to the
QRS complexes. Second, the resultant signal is fed to
the decision-making stage, which allows calculation of
HR from intermittent ECG periods of 30 s in duration,
based on a set of rules and empirically derived thresh-
olds, and provided that certain internal quality assurance
checks have been passed.
Part or all of each ECG segment may be severely cor-
rupted in some cases. For example, movement of the
ECG electrodes relative to the patient’s skin may gener-
ate transient voltages, which can be much larger than
the detected ECG waveform. Similar distortion can also
arise from static electricity coupling on to the patient’s
skin. This issue has been addressed in the algorithm by
implementation of additional rules and a number of
statistical estimators to verify the signal’s integrity. Thus,
segments of the ECG waveform deemed to be corrupted
—as ﬂuctuations in periodicity and amplitude of the
ECG segment do not meet preset experimental thresh-
olds—are automatically excluded from calculation of
HR. In addition, the entire segment is excluded and the
system reports an ‘invalid HR’ if the majority of the ECG
(ie, about 85% of the data segment) is corrupted.
The algorithm that quantiﬁes RR also comprises two
stages: a preprocessing stage that identiﬁes and ﬁlters
interference, and a postprocessing stage responsible for
detection of valid breathing cycles and calculation of
RR. The preprocessing stage includes a novel ﬁlter that
dynamically tunes its rejection frequency in accordance
with the HR obtained during the current monitoring
cycle, thereby attenuating any heart contaminants pro-
duced by dynamic changes in impedance due to inﬂow
and outﬂow of blood to the heart and great vessels.
A fundamental limitation of IP is that the primary
respiratory signal is easily corrupted by noise produced
by different electrical and mechanical sources (motion
artefact). To attenuate this type of noise, the algorithm
ﬁrst relies on autocorrelation (cross-correlation of the
detrended signal with itself)—enhancing signal periodi-
cities while suppressing aperiodic interference. The
resultant output is further analysed by a peak detection
and signal validity routine whose rules are heuristically
deﬁned in accordance with the expected characteristics
of the respiratory signal and thus, allows evaluation of
aspects such as signal periodicity and the number of res-
piration events detected from the autocorrelation peri-
odogram. As with the ECG, respiratory signals that are
severely corrupted by noise (variability in the respiration
peak to peak intervals of more than 25%) or lack appro-
priate respiration information (eg, when the patient
talks, swallows or coughs) are automatically discarded by
the system and a code indicating an invalid RR is trans-
mitted to the base station, when no periodic information
can be extracted from the signal. Otherwise, a valid RR
is calculated and transmitted. This ensures that only clin-
ically relevant RR values are transmitted to the caregiver,
thus minimising the occurrence of false alarms.
Data handling and statistical analysis
Raw signal data were collected from each patient, using
a personal computer running data-acquisition software
developed by Sensium Healthcare Limited (SHC). The
recorded data sets were then processed using a test-
bench interface also developed by SHC using MATLAB
(MathWorks Inc., Natick, Massachusetts, USA).
As discussed earlier, the digital patch algorithms were
speciﬁcally designed to automatically exclude data that
do not meet prespeciﬁed criteria. Data that failed to
meet these a priori quality standards were rejected; all
other data points were included in the analysis.
Individual patient ‘raw’ data were reviewed in MATLAB
by three of the investigators (MH-S, S-SA and SJB) to
determine whether data had been accepted or rejected
appropriately by the algorithm. It is important to
emphasise that the researchers were blinded from the
outputs of the automatic discrimination rules as they ran
inside the patch at the moment of acquiring and pro-
cessing the raw data.
Subsequently, spreadsheets were prepared containing
the HR and RR values from the digital patch together
with the corresponding values from the MP30 monitor.
The data were compared using simple Pearson’s correl-
ation, and the method of Bland and Altman.9 This
allowed for comparative estimates of bias (mean differ-
ence between values obtained by the two different
methods), and limits of agreement (±1.96×SD of the
mean difference between the two methods).
Estimates of data availability were also produced.
These were deﬁned as actual data points reported as a
percentage of total possible data points during the
recording period. This variable was intended to give a
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guide to the utility of IP as a means of estimating RR in
non-sedated patients as data rejection was anticipated
due to motion artefact, intermittent loss of electrode
contact or patch malfunction. Similar data were calcu-
lated for HR; this part of the system was anticipated to
be more robust.
RESULTS
Patient enrolment occurred between 22 October 2009
and 15 July 2010. Group 1 consisted of 20 patients
who underwent elective surgery at St Mary’s Hospital,
while group 2 comprised 41 patients who were
recruited from the clinic or ward areas of the hospital.
Patients were monitored for approximately 2 h. Bland
and Altman plots for the data from both groups are
presented in ﬁgures 2–4 and table 1. Individual
recordings are presented in the online supplementary
appendix.
In general, good agreement was seen between mea-
surements recorded with the wireless, digital patch
system and those obtained with the reference bedside
monitor.
Group 1 patients
Twenty patients were recruited (13 male, mean (SD)
age 49 (±16) years). Bland and Altman plots
(ﬁgure 2) showed a mean difference in HR of
−0.5 bpm between the digital patch and the bedside
monitor, with limits of agreement of ±3.47 bpm; 98.6%
of potentially available data were actually available
(table 1). For RR, the mean difference was 0.4 brpm,
with limits of agreement of ±6.7 brpm (ﬁgure 2); 64%
of potentially available data were actually available
(table 1). Correlation coefﬁcients were 0.99
(p<0.0001) for HR and 0.67 (p<0.0001) for RR. The
total numbers of data points corresponding to HR and
RR were 834 and 602, respectively.
Group 2 patients: cardiovascular disorders
Low voltage/variable QRS morphology (n=9, 7 male,
mean (SD) age 62 (±12) years)
The Bland and Altman plots are shown in ﬁgure 3A and
the proportion of data in table 1. The mean difference
in HR between the digital patch and the bedside
monitor was 0.97 bpm, with limits of agreement of
±4.7 bpm; 92% of potentially available data were actually
available. The mean difference in RR was −1.4 brpm,
with limits of agreement of ±9.4 brpm; 56% of data were
actually available. The correlation coefﬁcients were 0.98
(p<0.0001) for HR and 0.39 (p<0.0001) for RR. In total,
360 and 211 data points, respectively, corresponded to
available HR and RR values for this group.
Atrial fibrillation (n=10, 6 male, mean (SD) age 78 (±6)
years)
Results are shown in ﬁgure 3B and table 1. Very limited
usable data were obtained from this group—that is, only
217 pairs were available for HR and 99 for RR. For HR,
the mean difference between monitoring systems was
−1 bpm, with limits of agreement of ±7 bpm; 45% of
potentially available data were actually available. For RR,
the mean difference was −1 brpm, with limits of agree-
ment of ±8.4 brpm; 20% of the data were actually avail-
able. The correlation coefﬁcients were 0.96 (p<0.0001)
for HR and 0.22 (p=0.02) for RR.
Group 2 patients: metabolic disorders
High BMI (n=10, 4 male mean (SD) age 51 (±11) years)
Bland and Altman plots are shown in ﬁgure 4A and data
proportions in table 1. The mean difference in HR
between monitoring systems was 0.9 bpm, with limits of
agreement of ±4.4 bpm; 80% of potentially available data
were actually available. For RR, the mean difference was
−0.4 brpm, with limits of agreement of ±11 brpm; 54% of
data were available. The correlation coefﬁcients were
0.98 (p<0.0001) for HR and 0.48 (p<0.0001) for RR.
Figure 2 Comparison of heart and respiratory rate data between the wireless, digital patch monitoring system and the reference
bedside monitor during a 2 h monitoring period in patients who had undergone elective surgery (group 1 patients).
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In total, 347 and 199 data points, respectively, corre-
sponded to available HR and RR values for this group.
Diabetes (n=11, 9 male, mean (SD) age 51 (±11) years)
Results are shown in ﬁgure 4B and table 1. For HR, the
mean difference between monitoring systems was
−0.02 bpm, with limits of agreement of ±7 bpm; 77% of
data were available. The mean difference in RR was
0.1 brpm, with limits of agreement of ±7.8 brpm; 45% of
data were available. The correlation coefﬁcients were
0.97 (p<0.0001) for HR and 0.64 (p<0.0001) for RR.
The numbers of data points available for this group
were 545 and 314 for HR and RR, respectively.
DISCUSSION
To the best of our knowledge this was, at the time, the
ﬁrst trial of a system with miniaturised wireless monitor-
ing in a hospital clinical environment—using equipment
intended to monitor large numbers of patients
wirelessly.
Our study conﬁrmed that the SensiumVitals digital
patch provides reliable information on HR from patients
with normal sinus rhythm. Valid HR data were reported
for the majority of the time (typically >80%), even in
the presence of abnormal QRS morphology. When
patients with atrial ﬁbrillation were excluded, HR data
were reported with a mean difference of less than 1 bpm
compared with the IntelliVue monitor.
Although RR data were rejected as invalid more fre-
quently than HR data due to the nature of the IP tech-
nique, valid data were typically reported for 50% of the
time, providing a useful information update rate for the
caregiver. Accuracy was good when valid RR data were
reported, with a mean difference of less than 1 brpm
compared with the bedside monitor. The correlation
coefﬁcients were high for HR data (≥0.96) and lower
values were reported for RR, as would be expected with
the use of these two different measurement methods.
However, the correlation between methods was statistic-
ally signiﬁcant (p<0.0001), apart from patients with
atrial ﬁbrillation.
Figure 3 Comparison of heart and respiratory rate data between the wireless, digital patch monitoring system and the reference
bedside monitor during a 2 h monitoring period in patients with low voltage/variable QRS morphology (A) and patients with atrial
fibrillation (B).
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In patients with atrial ﬁbrillation, a large percentage
of the data were rejected as invalid for HR and RR.
Differences of up to ±6 were previously obtained when
the data were tested with those collected from a patient
simulator (SimMan, Laerdal Medical Ltd, Kent, UK;
data not shown) during an earlier pilot evaluation. Since
this arrhythmia is characterised by aperiodic R-R inter-
vals and irregular ECG morphology (eg, the absence of
P waves), it is entirely expected that the algorithm may
reject HR data. As previously discussed, it should be
borne in mind that part of the algorithm’s philosophy is
to reject such irregular waveforms and report them as
‘invalid’ to avoid false alarms due to motion artefact or
the transmission of data with low certainty of accuracy.
Transmission of falsely reassuring data would be poten-
tially hazardous.
When ECG data are rejected and no valid HR value is
generated, the ‘self-tunable’ ﬁlter in the RR algorithm
cannot be correctly centred. Consequently, the ﬁlter
may attenuate the valid respiration waveform, in which
Figure 4 Comparison of heart and respiratory rate data between the wireless, digital patch monitoring system and the reference
bedside monitor during a 2 h monitoring period in patients with a high body mass index (>30 kg/m2; A) and patients with diabetes
(B).
Table 1 Proportions of data from the wireless digital patch during continuous monitoring over a 2 h period; these data largely
reflect the patch algorithm rejecting data that did not pass the internal quality assurance step
Group
Heart rate
availability (%)
Respiratory rate
availability (%)
1 Operative 98.6 64
2 Low voltage QRS 92 56
Atrial fibrillation 45 20
High body mass index 80 54
Diabetes mellitus 77 45
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case an invalid signal may also be reported for RR,
explaining why respiration data for atrial ﬁbrillation
patients are reported as invalid for a signiﬁcant percent-
age of the time (80%). These ﬁndings led to the conclu-
sion that the digital patch, in its current form, is
unsuitable for use in patients with atrial ﬁbrillation or
other aperiodic arrhythmias.
Overall, RR was reported less frequently than HR, due
either to lack of regular HR data or to gross signal cor-
ruption due to motion artefact, an inherent issue with
IP-based methodologies.
From a clinical perspective, it is vital that monitoring
systems do not deliver falsely reassuring data, since this
may potentially prevent deteriorating patients from
receiving the attention they need. The modest level of
data availability under some circumstances, particularly
atrial ﬁbrillation, highlights two key points. First, the
digital patch algorithm is rejecting data appropriately.
Second, achievement of miniaturised wireless monitor-
ing presents real engineering challenges, particularly in
ambulatory patients.
However, the data acquisition technologies, as evalu-
ated in this study, form only one part of a clinical system.
The static network and processing components of the
system, plus the clinical protocols and routines, must be
designed to take account of the limitations of what we
can currently achieve with miniaturised vital signs moni-
toring devices. With the digital patch, the use of intelli-
gent algorithms to reject corrupted data is augmented
by automated notiﬁcations to advise the caregiver that
valid data have not been received from a patient for a
deﬁned period of time and that clinical review may be
required. Thus, the delivery of inaccurate, potentially
falsely reassuring data or the occurrence of false alarms
is minimised, while ensuring that surveillance of patient
status is maintained.
Other investigators have also demonstrated the
potential of wireless technology for remote surveil-
lance or management. Some have used implantable
devices: for example, the study of Abraham et al10
monitored pulmonary artery pressure intermittently in
heart failure; others have used equipment implanted
for other reasons.11 Wireless technology platforms are
being applied to increasing numbers of clinical situa-
tions: interesting examples have been described for
diabetes management,12 remote monitoring of home
ventilatory support,13 and investigation of gastrointes-
tinal disease.14 Preliminary studies using the Vitalsens
device (VS100: Intelesens Ltd, Northern Ireland),
which can record and transmit similar parameters to
the SensiumVitals digital patch, have been promising
and have conﬁrmed proof of general concept.
The former device, however, is philosophically very
different—being larger and reusable in design—in
contrast to the single-use miniaturised disposable
SensiumVitals.15–17
The objectives of this study were met, as agreement
between methods and rejection of corrupted data were
demonstrated for the miniaturised wireless digital patch
under the majority of circumstances tested.
A limitation of this study is related to the short dur-
ation of the data collection intervals and the number of
participants available, given the conditions of the work-
ﬂow in these critical settings. However, it should be
borne in mind that this was a preliminary feasibility
study and therefore, a further clinical evaluation with a
signiﬁcant sample of participants in the general ward
must be carried out to reafﬁrm the outcomes of this
investigation. In addition, in this preliminary study,
patients were monitored at rest and thus, we can make
no assumptions concerning performance with patients
moving around in a truly ambulatory context.
Wireless technologies for measurement of vital signs,
such as the one used in this study, have now developed
to the point where they have the potential to make a
substantial contribution to patient safety. Evaluation of
end-to-end system performance within the hospital
environment will provide further information on the
clinical value and acceptance of the wireless monitoring
system in routine practice as part of a wider system to
augment and support existing clinical protocols and
workﬂows.
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